Company profile

Novo Nordisk

Biopharma, diabetes, obesity, rare disease · Bagsværd, Denmark · novonordisk.com

Novo Nordisk is a global healthcare company focused on diabetes, obesity, rare diseases, with a long operating history and a large international commercial and manufacturing footprint. Its current direction emphasizes capacity expansion, R&D productivity, digital transformation across research, supply, commercial operations.

Strategic priorities

Obesity and diabetes growth

The company says it is prioritizing obesity and diabetes growth opportunities and reinvesting savings into those areas.

2025 annual report states 2026 annualised savings from workforce reduction will be redirected to obesity and diabetes growth opportunities.

2025 at a glance

R&D and innovation engine

The company is directing capital and operating focus toward new therapies and broader pipeline output.

2025 annual report says R&D spending increased and the R&D organization was reconfigured into a more seamless end to end engine.

Innovation and therapeutic focus

Operational capacity expansion

It is still investing in production and supply capacity to meet demand.

2025 report says capital expenditure went primarily to additional API and fill finish capacity for current and future injectable and oral products.

Financial performance

Digital transformation

Digital tools are positioned as a core enabler of efficiency and process scale.

Novo Nordisk says its digital strategy is transforming every level of the business and focuses on optimize, augment, explore.

Digital Strategy

AI program

Novo Nordisk publicly describes AI as established across research, development, supply, commercial work, with an AI center of excellence, GenAI tools, a data and AI ethics framework. In April 2026 it announced a strategic AI partnership that it said would apply advanced AI from drug discovery to commercial operations, with human oversight and data governance. It also says AI is used to accelerate discovery, analyze complex datasets, improve productivity across the value chain.

Technology posture

The company presents technology as a business enabler, with cloud, data, automation, AI embedded in a broader digital transformation agenda.

Cloud

3/5

4/5

Data

4/5

Public materials emphasize data management, analytics, integrations, cloud and infrastructure, plus governed AI use across R&D and operations.

Technology vendor categories

OpenAI, Valo Health

Data

IQVIA

Cloud

n/a

ERP

n/a

Security

n/a

DevOps

n/a

Cited technology signals

Public, sourced evidence of the third-party technology this company uses, from careers pages, filings and press.

Novo Nordisk announced a strategic partnership with OpenAI and said it will integrate OpenAI's advanced AI capabilities globally from drug discovery to commercial operations.

Press98% confidencesource

Novo Nordisk said it rebuilt over 50 websites on Adobe Experience Manager cloud and executed 100+ micro-experiences per year through Adobe Experience Platform.

Press50 matching job posts96% confidencesource

Adobe said Novo Nordisk uses Adobe Experience Platform with Adobe Real-Time CDP, Adobe Journey Optimizer, Adobe Customer Journey Analytics, Adobe Workfront to deliver personalized omnichannel experiences.

Press95% confidencesource

Novo Nordisk's 2025 annual report says market data are based on moving annual total data provided by the independent data provider IQVIA.

Filing94% confidencesource

Novo Nordisk's careers site says its Foundational IT program focuses on cloud and infrastructure, integrations, data management and analytics, global platforms.

Careers88% confidencesource

Recent developments

Sources

Get the full sourced brief on Novo Nordisk

This is a neutral public preview. Sign in to generate your own personalized brief, with stakeholder angles, talk tracks and where your solution fits, tailored to how you sell.

Generate a full brief

Your first brief is free, no card required.

Evidence confidence 86/100. Generated 2026-07-03 from public sources.